摘要
背景:帕金森病(PD)是一种慢性进行性疾病,是世界上第二常见的神经退行性疾病。经典特征包括:运动迟缓,静息震颤。r,刚性和溃烂。这些神经改变可能是由于黑质致密部多巴胺能神经元死亡和多巴胺输入减少所致。纹状体。多巴胺水平的降低也可能与非运动症状的出现有关,包括认知障碍、焦虑和抑郁症状。神经营养因子(NF)Ar调节神经元功能、发育和存活的蛋白质。据报道,NF可能在PD中发挥保护作用。 目的:探讨临床前和临床研究中有关神经营养因子(NF)在帕金森病(PD)中的作用及其作为有前途的治疗策略的潜力的新证据。 方法:在PubMed中心进行广泛的文献检索。 结果:应用NF治疗PD的临床前研究可能由于方法上的差异而存在差异,从而排除了任何结论。与行政管理有关的临床研究结果NF在PD患者中的浓度更令人失望。另一方面,临床前和临床上的研究普遍支持体力活动是一种低成本、非药理学的策略。治疗PD效果良好。 结论:应用NF治疗帕金森病仍是一项尚未纳入临床实践的承诺。注射NFS的方法、剂量和化合物、副作用、种群特征抽搐和病程可能导致不成功的结果。
关键词: 帕金森病,神经营养因子,BDNF,GDNF,MPTP,6-OHDA.
Current Medicinal Chemistry
Title:Neurotrophic Factors in Parkinson’s Disease: What Have we Learned from Pre-Clinical and Clinical Studies?
Volume: 25 Issue: 31
关键词: 帕金森病,神经营养因子,BDNF,GDNF,MPTP,6-OHDA.
摘要: Background: Parkinson´s Disease (PD) is a chronic, progressive condition, being the second most common neurodegenerative disorder worldwide. The classical features include: bradykinesia, resting tremor, rigidity and festination. These neurological alterations are probably due to the death of dopaminergic neurons in the Substantia Nigra pars compacta and consequent reduction of dopamine input into the striatum. The decrease of dopamine levels may also be involved in the emergence of non-motor symptoms, including cognitive impairment, anxiety and depression symptoms. Neurotrophic Factors (NF) are proteins that modulate neuronal function, development, and survival. It has been reported that NF might exert a protective role in PD.
Objective: We aim to discuss the emerging evidence from pre-clinical and clinical studies regarding the role of NF in PD as well as their potential as promising therapeutic strategies.
Methods: We carried out an extensive literature search in PubMed central.
Results: Pre-clinical studies using NF to treat PD are divergent probably due to several methodological differences, thus precluding any conclusion. Clinical studies findings obtained with the administration of NF in patients with PD were even more disappointed. On the other hand, pre-clinical and clinical studies generally support that physical activity is a low-cost, non-pharmacologic strategy with good results to treat PD.
Conclusion: The use of NF as a treatment for PD is still a promise not incorporated in clinical practice. Methods to deliver NFs, doses and compounds administered, side effects, population characteristics and duration of disease may probably contribute to the unsuccessful results.
Export Options
About this article
Cite this article as:
Neurotrophic Factors in Parkinson’s Disease: What Have we Learned from Pre-Clinical and Clinical Studies?, Current Medicinal Chemistry 2018; 25 (31) . https://dx.doi.org/10.2174/0929867325666180313101536
DOI https://dx.doi.org/10.2174/0929867325666180313101536 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Depressed or Demented: Common CNS Drug Targets? !
Current Drug Targets - CNS & Neurological Disorders Delivery Systems for Applications in siRNA Technology
Drug Delivery Letters Adenosine Deaminase in the Modulation of Immune System and its Potential as a Novel Target for Treatment of Inflammatory Disorders
Current Drug Targets FoxO3a Governs Early Microglial Proliferation and Employs Mitochondrial Depolarization with Caspase 3, 8, and 9 Cleavage During Oxidant Induced Apoptosis
Current Neurovascular Research Neuropeptide Receptor Ligands for the Treatment of Schizophrenia: Focus on Neurotensin and Tachykinins
Current Pharmaceutical Design Multivalent & Multifunctional Ligands to β-Amyloid
Current Pharmaceutical Design Inducers of Heme Oxygenase-1
Current Pharmaceutical Design Cholinergic System and Post-translational Modifications: An Insight on the Role in Alzheimer's Disease
Current Neuropharmacology Molecular Mechanisms Regulating Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: NeuroAIDS: Past, Present and Future)
Current HIV Research Astrocytes and Gliotransmitters: New Players in the Treatment of Major Depression?
Current Drug Targets Muscle Atrophy Classification: The Need for a Pathway-Driven Approach
Current Pharmaceutical Design Editorial [Hot Topic: Nitric Oxide: Implications for the Etiology & Treatment of Central Nervous System Disorders (Guest Editor: Giuseppe Di Giovanni)]
CNS & Neurological Disorders - Drug Targets Glycogen Synthase Kinase-β3 in Ischemic Neuronal Death
Current Neurovascular Research Biological Markers of Alzheimers Disease and Mild Cognitive Impairment
Current Alzheimer Research Metabotropic Glutamate Receptors as Drug Targets
Current Drug Targets Cannabinoid Receptor Type 2 Activation Yields Delayed Tolerance to Focal Cerebral Ischemia
Current Neurovascular Research The Positive Synergism of CPT and MK-801 in Behavioral Tests and in Reduction of Environmental Stress and Redox Signaling Changes in Mice Cerebral Cortex
CNS & Neurological Disorders - Drug Targets Mitophagy in Neurodegeneration: An Opportunity for Therapy?
Current Drug Targets Parkinson’s Disease: Alpha Synuclein, Heme Oxygenase and Biotherapeutic Countermeasures
Current Pharmaceutical Design